Intellipharmaceutics International Inc. (NASDAQ: IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its United States subsidiary,Intellipharmaceutics Ltd., has appointed Ira Baeringer as its Vice President, Business Development, effective February 1, 2012.
Mr. Baeringer will be assisting Intellipharmaceutics with the commercialization of products in its controlled-release generic drug Abbreviated New Drug Applications (ANDA) portfolio and 505(b)(2) New Drug Application (NDA) portfolio across markets inside and outside the United States. Mr. Baeringer brings 20 years of experience in pharmaceutical licensing, development, supply, acquisitions, divestitures, and alliance management. He was most recently with sanofi-aventis from 2009 to 2012, and was previously with Sandoz Inc., Dorland Sweeney Jones, Forest Pharmaceuticals, Inc. and TEVA Pharmaceuticals USA.
“We are pleased to have Ira join the Intellipharmaceutics team as we build our leadership group and infrastructure to help position us for growth and expansion of our core business,” stated Dr. Isa Odidi, CEO. “His experience will be of great value as Intellipharmaceutics continues to pursue implementation of its commercialization plans in the U.S. market through the exploration of new drug product opportunities and new strategic partnerships.”
“I am pleased to be joining Intellipharmaceutics at this exciting time in the Company’s history,” said Mr. Baeringer. “I believe the six product candidates filed with the FDA for regulatory approval will form a solid base to develop near term strategic partnerships and build out our commercial capabilities.”
About Intellipharmaceutics
Intellipharmaceutics International Inc., operating through its subsidiaries, is a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix(TM) technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals.
Based on this technology, Intellipharmaceutics has a pipeline of products in various stages of development, including six ANDAs under review by the FDA, in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection.
Press Release: Intellipharmaceutics International Inc.
“Be fearful when others are greedy, and be greedy when others are fearful.” – Warren Buffett
If you really want to make some considerable profits from the stock market, it is possible to make a considerable amount of money on penny stock trading. When you find the right penny stock to buy, knowing when to buy and sell is the second most important tool to maximizing your profits.
Being technical, analytical or just flat-out greedy when trading penny stocks is the easiest way to limit profits and, sometimes, even lose your entire investment. You need to have a strong and strict strategy to achieve your goal of maximizing profits while minimizing risks in penny stocks.
Listed below are a few of the many points each and every penny stock investor needs to discover.
- Do your own research.
- Trade Responsibly.
- Verify everything.
- Move Fast or Get Left Behind.
- Do not use market orders to enter a position, use limit orders.
- Have a System That fits You.
- If a Stock Gaps Open, Look for Pullbacks to Enter.
- Plan a Trade and Trade a Plan.
- Always use stop loss orders to protect yourself.
- Positive Self- Belief.
- Keep trading as Part of a Balanced life.
- If a stock breaks below our alert price GET OUT. Do not wait.
- View Trading as a Score in Points and Not In Money:
- Always take your profits whenever you can. Do Not Be Greedy.
- Work Hard at Learning How to Trade Properly and Keep Working.
- Do something to make someone else’s life better today.
About AimHighProfits.com
AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential.
Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.
We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.
Aim High Profits Disclaimer
This is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision.
Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
For a complete explanation, please visit our disclaimer page.
ShareJAN
